相关实验视频

Updated: May 23, 2025

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

氨酸A2A受体激活减轻了小鼠患有系统性Candida albicans感染的疾病,通过调节巨细胞功能来感染

Xia-Nan Wu¹, Ke Dong¹, Yan Liu¹

¹Department of Clinical Laboratory, Tangdu Hospital, Airforce Medical University, Xi'an, Shaanxi, People's Republic of China.

Journal of inflammation research

|March 11, 2025

概括

激活腺A2A受体 (A2AAR) 增强了巨细胞的抗真菌活性和M2极化,改善了系统性Candida albicans感染中的生存率. 这表明A2AAR激活是一种有前途的治疗策略.

科学领域:

免疫学免疫学免疫学
传染性疾病传染性疾病
药理学药理学是指药理学的学科.

背景情况:

系统性 *Candida albicans* 感染或候选血症正在增加,需要对疾病机制和治疗点进行研究.
了解腺信号传递在候选血症中的作用对于开发新疗法至关重要.

研究的目的:

为了研究腺-腺受体信号传导在系统性*Candida albicans*感染中的作用.
评估针对候选血中的腺受体的治疗潜力.

主要方法:

通过静脉注射 *C. albicans* 建立了一种小鼠候选血病模型.
用NECA (腺类型) 或腺受体激动剂 (A1R,A2AR,A2BR,A3R) 治疗的小鼠.
评估的生存率,脏真菌负荷,组织损伤和巨细胞功能 (细胞分裂,杀死,极化).

主要成果:

接受NECA和A2AR激动剂治疗显著提高了存活率,并减少了候选症小鼠的损伤和真菌负荷.
A2AR激活减少了脏巨细胞的透和IL-6的产生.
氨酸-A2AR信号增强了巨细胞的抗真菌能力,并促进了M2极化.

结论:

腺-A2AR轴的激活增强了对系统性*C. albicans*感染的宿主防御.
A2AR激活促进M2巨细胞的两极分化,并缓解候群病.
向A2AR通路代表了治疗候选血病的潜在治疗策略.

关键词:

在C. albicans中,它是最重要的.腺素受体的受体是什么?巨细胞是一个巨细胞.造成的损伤.系统性感染系统性感染

更多相关视频

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Published on: June 16, 2023

相关概念视频

Adrenergic Receptors: ɑ Subtype

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...